cyclin and CBS domain divalent metal cation transport mediator 2Genealiases: ACDP2 · HOMG6 · HOMGSMR · SLC70A2
Q-omics provides the consensus-scored CNNM2 profile across patient tissues and cancer cell-line models. CNNM2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNNM2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CNNM2 RNA expression shows 21,311 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where CNNM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNNM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNNM2 survival associations across molecular data types. CNNM2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNNM2 RNA expression–survival associations across cancer types. High CNNM2 expression shows unfavorable associations in UVM, ACC and BLCA, but favorable associations in KIRC, LGG and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNNM2 RNA expression.
This table summarizes CNNM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CNNM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNNM2 shows lower tumor expression in COAD, THCA, KIRP and KIRC and higher tumor expression in HNSC and LIHC. The COAD box plot shows higher CNNM2 RNA expression in normal versus tumor tissue (log2 FC = −1.549, t-test p < 0.001).
This table shows molecular features associated with CNNM2 in patient tissues and cancer cell lines. In patient samples, CNNM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CNNM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
